BARK Migrates to Ordergroove and Shopify to Unleash New Subscriber Experiences
'Working with Ordergroove and Shopify strengthens the technology that powers our business and gives us the flexibility to deliver more personalized, seamless subscriber experiences."
Share
The move unifies BARK's customer experience and recurring revenue onto a single scalable tech stack, reducing cost and complexity while unlocking new, innovative subscriber experiences across BarkBox, Super Chewer, and BARK Bright. It also builds on the brand's recent momentum, with fiscal Q1 2025 marking BARK's strongest direct-to-consumer gross margin quarter to date, underscoring its commitment to operational efficiency and customer experience.
Previously, BARK managed two separate subscription platforms, which required significant engineering resources, increased technical debt and limited its ability to build on key growth initiatives such as bundles, memberships, prepaid programs, and enhanced promotional capabilities.
'At BARK, our mission is to make dogs, and their people, happy,' said Meghan Knoll, Chief Experiences Officer at BARK. 'Working with Ordergroove and Shopify strengthens the technology that powers our business and gives us the flexibility to deliver more personalized, seamless subscriber experiences. With this new foundation, we're better positioned to innovate, scale efficiently, and deepen the connection between dogs and their humans — all while driving sustainable growth.'
Designed with their millions of customers in mind, BARK's new infrastructure empowers the brand to create more tailored subscriber experiences while reducing operational complexity. From flexible delivery models like Subscribe & Save to curated memberships and bundles, Ordergroove now powers every aspect of BARK's recurring revenue.
Additionally, the brand can now test and launch advanced promotions, personalize upsells and cross-sells, and optimize SKU performance to maximize CLTV. Ordergroove's Rotating Clubs also allow BARK to curate boxes from a single SKU catalog, driving product discovery while simplifying operations.
BARK's migration underscores a growing trend among enterprise brands to consolidate their subscription infrastructure, choosing deeply integrated platforms that provide both scalability and flexibility for customization. With Ordergroove and Shopify, BARK is well-positioned to drive sustained growth, enhance customer engagement, and create more meaningful experiences for dog parents worldwide.
'BARK is a standout example of what's possible when brands invest in deep, lasting relationships with their customers,' said Greg Alvo, CEO of Ordergroove. 'We understand how special the relationship is between dog parents and their dogs, and we're excited to help BARK strengthen that connection through flexible and engaging subscriber experiences. This partnership exemplifies how Ordergroove and Shopify empower brands to scale, optimize customer retention, and unlock new growth opportunities.'
"BARK's migration to Shopify demonstrates the power of our Shopify platform in supporting complex subscription models and high-volume operations for leading brands," said Josh Rice, VP of Commercial at Shopify. "This partnership with Ordergroove showcases how Shopify enables brands to consolidate their tech stack, reduce operational complexity, and unlock new growth opportunities while delivering exceptional customer experiences."
For more information about BARK, visit www.bark.co. To learn more about Ordergroove's subscription solutions, visit www.ordergroove.com.
ABOUT BARK
BARK is the world's most dog-centric company, devoted to making dogs happy with the best products, services and content. BARK's dog-obsessed team applies its unique, data-driven understanding of what makes each dog special to design playstyle-specific toys, wildly satisfying treats, dog-first experiences that foster the health and happiness of dogs everywhere, and more. Founded in 2011, BARK loyally serves millions of dogs nationwide with BarkBox and Super Chewer, its themed toys and treats subscriptions; custom product collections through its retail partner network, including Target, Chewy, and Amazon; and BARK Air, the first air travel experience designed specifically for dogs first. At BARK, we want to make dogs as happy as they make us because dogs and humans are better together. Sniff around at bark.co for more information.
Ordergroove enables subscription and membership experiences for the world's largest and most innovative brands and retailers, including L'Oréal, Dollar Shave Club, Daily Harvest, Grove Co, Bonafide Health and Petsmart. As a market leader in subscription and membership technology, the company's proprietary Relationship Commerce platform is shifting consumer interactions from one-and-done transactions to frictionless and highly-profitable recurring relationships. Ordergroove technology uses artificial intelligence, analytics, and unmatched consumer expertise to empower top brands to transform their commerce experiences while making their consumers' lives easier. To learn more, visit www.ordergroove.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
3 Dow Jones Dividend Stocks With Above-Average Yields You Can Buy Now and Hold for at Least a Decade
Key Points UnitedHealth Group's reduced profit forecast for 2025 is disappointing, but the health insurance business is in a good position to bounce back. Coca-Cola's dividend payout has risen for 63 consecutive years. Amgen sells over a dozen drugs that are growing sales at a double-digit annual percentage. 10 stocks we like better than UnitedHealth Group › Income-seeking investors who value their time know the best dividend stocks don't need a lot of babysitting. Some go on decades-long payout-raising streaks. The Dow Jones Industrial Average (DJINDICES: ^DJI) is one of the best places to find reliable dividend payers. Stocks aren't added to this exclusive list unless they have already demonstrated an ability to produce profits in good economic times and bad ones, too. The average dividend payer in the Dow Jones Industrial Average offers a measly 1.6% yield at recent prices. UnitedHealth Group (NYSE: UNH), Coca-Cola (NYSE: KO), and Amgen (NASDAQ: AMGN) stand out with above-average yields. Here's why they could be great additions to a long-term dividend investor's portfolio. 1. UnitedHealth Group Shares of UnitedHealth Group collapsed in May, after the company simultaneously suspended its 2025 outlook and announced an abrupt CEO exit. To top it off, the company felt it was necessary to issue responses to several Wall Street Journal articles and a Department of Justice investigation regarding its Medicare business. The stock is down, but its dividend payout is way up. The company raised it by 76.8% over the past five years. At its beaten-down price, the stock offers a 2.7% yield. Health insurance businesses operate on thin margins. It turns out that UnitedHealth mispriced premiums going into 2025. Healthcare providers are charging more than the company anticipated, plus the amount of care new members have been using is also higher than expected. Smart investors such as Warren Buffett know that UnitedHealth Group is mostly a middleman that can pass increased costs on to health plan sponsors. It may have mispriced premiums going into 2025, but this isn't a mistake its recently refreshed management team is likely to make again in the decade ahead. 2. Coca-Cola Unlike UnitedHealth, Coca-Cola stock is up near its all-time high. The soda giant's dividend hasn't risen as sharply as the health insurer's, but it's still up by 24.4% over the past five years. Being the only company that can sell many of the world's most popular beverage brands is a strong advantage that leads to consistent profits. In February, the company announced a dividend raise for the 63rd year in a row. Shares of Coca-Cola offer a 2.9% yield at recent prices, and another decade of significant dividend raises isn't an unreasonable expectation. Second-quarter unit case volume fell by 1%, but the strength of its brands allowed organic revenue to rise by 5% year over year. Sales of sugary sodas have been losing ground to sports drinks, but the company has this base covered. Its BodyArmor brand boasts a double-digit share of the U.S. market, and its older Powerade brand is even more popular. Adding some shares of this stock to a diverse portfolio is an almost certain way to boost your passive income stream over time. 3. Amgen Shares of biotechnology pioneer Amgen have been trading about 12% below the all-time high they set last year. Amgen began paying a dividend in 2011 and has been able to increase it every year since. The drugmaker raised its payout by 48.8% over the past five years. At recent prices, it offers a 3.2% yield. Two of Amgen's top revenue streams, Enbrel and Prolia, are drying up thanks to biosimilar competition. Fortunately, the losses are easily offset by a slew of more recently launched products. Amgen recently reported year-over-year sales increases at a double-digit percentage for 15 products in the second quarter. New competition for Enbrel and Prolia limited second-quarter sales growth to 9% year over year. Enbrel and Prolia losses will most likely reach a bottom long before Amgen's new growth drivers run out of fuel. With a strong lineup of new products, this company could report strong sales growth in the decade ahead. Should you buy stock in UnitedHealth Group right now? Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,077% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy. 3 Dow Jones Dividend Stocks With Above-Average Yields You Can Buy Now and Hold for at Least a Decade was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
Shopify's high valuation could be a risky bet even as its stock price skyrockets: Analyst
Shopify ( briefly overtook Royal Bank of Canada ( this month to become the country's most valuable company, fuelled by investor excitement over its second-quarter earnings. However, a question remains: is its lofty valuation justified? On Aug. 6, the company's market cap surged to $276 billion as its shares climbed over 20 per cent after the e-commerce giant posted Q2 profit of US$906 million, a jump from the US$171 million it earned in the same quarter last year. Shopify's market cap has since fallen to $248.5 billion, putting it back below RBC's. Shopify's growth is, in part, fuelled by optimism around its new AI tools, including an AI-powered store builder, a universal cart that allows shoppers to buy from multiple stores in a single checkout, and a new product discovery tool called Catalog. User feedback on platforms like Reddit and X suggests that existing AI integrations, such as the AI assistant Sidekick, are already resonating with merchants, says Martin Toner, an analyst at ATB Capital Markets. This positions Shopify as a strong contender to benefit from the AI boom, he adds. While Shopify has the potential to be a genuine AI-era growth engine, the stock already trades as if it is, which makes it risky and leaves less room for further upside. Following Shopify's second-quarter earnings, Toner downgraded the stock from "outperform" to "sector perform." He explains his decision by noting that the stock was trading at more than 15 times its price-to-sales ratio. The company has about 50 per cent gross margin, so that means it's trading at 30 times gross profit and even higher on a real bottomline profit multiple like EBITDA, Toner says. 'At some point, it's just hard for them to grow into that high valuation,' he added. Using a discounted cash flow model, Toner notes, the company would need to compound its growth at 25 per cent for 10 years and reach "well over a trillion dollars" in gross merchandise value, making it difficult to justify much more upside, he says. Potential winner However, Toner acknowledges that Shopify's high price-to-earnings ratio of 76.5 implies a significant amount of future growth and margin expansions. If the company can grow by 30 per cent and double its margins, the price-to-earnings ratio could fall to 30x, he says, a multiple similar to that of Microsoft. In this context, Toner says, 'it is not that hard to grow into.' He also notes that Shopify does stand out as a potential winner in the age of AI because it's not spending as much on capital expenditure as global tech giants like Google and Microsoft. While some tech companies succeeded over the last decade by not spending heavily on hard assets, that is changing as many invest significant sums in AI data centres and other capital projects. With Shopify, that isn't the case. 'So that's worth a premium,' Toner said, adding that it's just hard to say how much of a premium. National Bank analyst Richard Tse, who maintained his "outperform" rating on Shopify after its Q2 earnings, says the company's use of AI reinforces 'Shopify's leadership as it relates to how Shopify applies the technology in its operations to its platforms and services.' He also restated previous remarks that AI is becoming a structural growth and profitability lever for Shopify. The only 'scary downside,' Toner says, other than valuation, is Shopify's payments model. Because of a related product called Shop Pay, a one-tap check-out service, more merchants are using Shopify payments. According to Toner, a three per cent gross merchandise fee is charged to merchants, with about two-thirds going to parties involved in the transaction (like a financial institution), and about one-third of that is kept with Shopify. If a new competitor or a change in the market were to challenge this payment model, Shopify could come under threat, he adds. For retail investors, however, Toner's recommendation is to hold the stock right now. 'On an absolute basis, I think risk/reward is fair value,' he said, at the same time giving some advice to first-time investors: 'In a world where you have a lot of options, you'll probably find a better idea somewhere else.' Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Combination Cancer Therapies Surge: The Young Adult Treatment Revolution
As cancer rates climb 30% among adults under 50, combination immunotherapy companies are advancing breakthrough treatments and institutional investors are committing $243.62 billion to capture the rapidly expanding precision oncology market. A medical crisis is reshaping the cancer treatment landscape. Young adults under 50 are experiencing unprecedented cancer rates, with aggressive tumors requiring innovative combination approaches that go far beyond traditional single-drug therapies. According to Memorial Sloan Kettering Cancer Center, cancer incidence rates in women under 50 are now 82% higher than their male counterparts, up from 51% in 2002. The American Cancer Society reports that colorectal cancer has become the leading cause of cancer deaths among young men and the second leading cause among young women, fundamentally changing treatment priorities across the oncology spectrum. The market response reflects this urgency. Mordor Intelligence projects the global cancer therapy market will surge from $243.62 billion in 2025 to $403.99 billion by 2030, reflecting a 10.64% CAGR driven by demand for combination therapies specifically designed to combat the more aggressive cancers plaguing younger demographics. Keep reading to discover how combination immunotherapy approaches are revolutionizing treatment for young adult cancer patients and which companies are positioned to dominate this rapidly evolving market. For a detailed analysis of one company leading this transformation, click here. Leading Companies in the Combination Therapy Revolution Combination immunotherapy is attracting significant institutional investment, with these companies making strategic moves: AstraZeneca PLC (NASDAQ: AZN) --- AstraZeneca recently received FDA Priority Review and Breakthrough Therapy Designation for its Imfinzi immunotherapy in early-stage gastric cancers, with FDA decision anticipated in Q4 2025. The perioperative combination regimen showed a 29% reduction in disease progression risk, positioning the company to capture significant market share as gastric cancers increasingly affect younger populations with more aggressive disease patterns. Bristol Myers Squibb Company (NYSE: BMY) --- Bristol Myers Squibb recently secured FDA approval for its Opdivo-Yervoy combination as first-line treatment for unresectable liver cancer, converting a previous accelerated approval. The dual checkpoint inhibitor regimen directly competes with rival immunotherapy combinations and offers potential for longer survival compared to traditional targeted therapies, particularly relevant as liver cancers show rising incidence in younger adults. Amgen Inc. (NASDAQ: AMGN) --- Amgen recently gained FDA approval for Imdelltra, its breakthrough bispecific T-cell engager for extensive-stage small-cell lung cancer, with pricing at $31,500 per first cycle. The drug demonstrated a tripling of survival duration to 14.3 months median overall survival in a disease where median survival typically reaches only 5 months, addressing the urgent need for effective treatments in the deadliest form of lung cancer. Pfizer Inc. (NYSE: PFE) --- Pfizer recently showcased breakthrough data across its oncology portfolio at ASCO 2025, featuring combination approaches in breast, genitourinary, and thoracic cancers. The company's Braftovi combination doubled survival time for patients with aggressive colorectal cancer in late-stage trials, representing significant progress for a cancer type that disproportionately affects younger adults with traditionally poor prognosis and limited treatment options. The $403.99 Billion Combination Therapy Opportunity The convergence of rising young adult cancer rates and breakthrough combination immunotherapies is creating unprecedented market expansion across every segment of oncology treatment. Read: Mining Stocks Finally Wake Up as Gold Stays Hot Above $3,300 $40 Silver Breakout Imminent as Miners Enter High-Momentum Phase Encryption Is Dying—Here's What Comes Next for Cyber Defense FDA Fast-Track Cancer Treatments Drive $900B Market Growth Forecast Mining Stocks Outpace Gold's Historic Rally as Sector Primes for Breakout According to Mordor Intelligence, the global cancer therapy market will reach $403.99 billion by 2030, with combination immunotherapies representing the fastest-growing segment. The shift toward treating younger patients with more aggressive cancers requiring multi-drug approaches is fundamentally altering treatment economics and creating new revenue opportunities for companies developing sophisticated combination regimens. Precedence Research forecasts the cancer therapeutics market will expand from $194.67 billion in 2024 to $469.38 billion by 2034, representing a 9.20% CAGR. This explosive growth is being driven by the unique challenges of treating younger patients whose cancers often resist single-agent therapies and require novel combinations of checkpoint inhibitors, targeted therapies, and next-generation immunomodulators specifically designed for aggressive tumor biology. Global Market Insights projects the oncology market will reach $866.1 billion by 2034, growing at a 10.8% CAGR. The market expansion is being accelerated by the urgent need to address the 30% surge in young adult cancer cases projected through 2030, with combination therapies representing the most promising approach to combat the treatment-resistant, aggressive cancers increasingly diagnosed in this demographic. The Bottom Line The combination therapy revolution is accelerating rapidly, driven by the unprecedented cancer epidemic affecting young adults who require more sophisticated treatment approaches than traditional single-drug regimens can provide. With aggressive cancers becoming more prevalent in younger demographics, the demand for innovative combination immunotherapies is creating massive market opportunities. Institutional investors are positioning for explosive growth as companies develop next-generation combination platforms specifically designed to address the unique molecular characteristics and treatment resistance patterns exhibited by cancers in younger patients. While the companies mentioned represent established leaders in combination therapy development, one innovative biotech has quietly advanced a viral immunotherapy platform that combines multiple mechanisms of action in a single treatment approach. To learn more about this emerging opportunity, click here.
